Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
基本信息
- 批准号:8633430
- 负责人:
- 金额:$ 66.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2016-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsBasic ScienceCancer ModelCancer PatientClinicClinicalClinical TrialsComplexContrast MediaDataDiagnosticDisease ProgressionDistalDosage FormsDoseDrug KineticsEpithelial ovarian cancerFolateGadoliniumGoalsHumanImageIn VitroInvestigationKnowledgeLaboratoriesLightLinkLocalized DiseaseMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of ovaryMedicineModalityModelingMorphologyMulti-Drug ResistanceMusNanotechnologyNeoplasm MetastasisNewly DiagnosedNormal tissue morphologyOutcomePaclitaxelPharmaceutical PreparationsPhenotypePlasmaPolysorbate 80RattusRecurrenceRecurrent Malignant NeoplasmRecurrent diseaseRecurrent tumorRefractoryRegimenResearch PersonnelSafetySolutionsSystemTechnologyTherapeutic AgentsTimeTissuesToxic effectTransgenic MiceTranslatingTreatment EfficacyTreatment ProtocolsValidationXenograft procedurebasecancer therapychemotherapeutic agentcombatcytotoxicitydesigndocetaxeleffective therapyexhaustexperiencegadolinium oxidehuman FOLR1 proteinimprovedin vivoinnovationinsightintraperitonealmalignant breast neoplasmmanmortalitymouse modelnanocarriernanoemulsionnanomedicinenovelovarian neoplasmpreclinical studyresidencetumoruptake
项目摘要
DESCRIPTION (provided by applicant): During treatment recurrent cancers build up multidrug resistance to conventional and novel chemotherapeutic agents representing a formidable challenge in clinical cancer therapy, especially for the effective treatment of gynecological malignancies. This R01 proposal describes a targeted-, combination imaging agent and therapeutic nanoemulsion, designated NMI-500, designed to provide timely diagnostic information on where the co-deliver treatment is accumulating and provide clinicians the quantitative insight to adjust treatment schedules in light of this new information. A team of investigators from two commercial and two academic organizations will collaborate to develop this clinically translatable strategy, initially addressing recurrent multidrug resistant phenotype. NMI-500 uses folate to specifically target docetaxel (DTX), and gadolinium (Gd) an MR imaging agent to localized disease as well as distal metastases. NMI-500's targeting moiety folate is known to improve uptake by tumors expressing folate receptor alpha (FR-a). FR- a, largely absent from normal tissue, has been shown to be over expressed on >80% of recurring ovarian tumors. In breast cancer high FR-an expression has been linked to poor clinical outcomes. The imaging component of NMI-500 will be achieved with the MRI contrast agent Gd, which has been shown to enhance contrast efficiency when conjugated to a nanoemulsion.1 Specific aims will assess and validate the imaging, targeting, efficacy and pharmacokinetics of the combination imaging/chemotherapeutic product, NMI-500.
描述(申请人提供):在治疗期间,复发癌症对传统和新型化疗药物产生多重耐药性,这是临床癌症治疗中的一个巨大挑战,特别是对妇科恶性肿瘤的有效治疗。这份R01提案描述了一种名为NMI-500的靶向、组合显像剂和治疗性纳米乳剂,旨在提供有关联合治疗在哪里积累的及时诊断信息,并为临床医生提供量化洞察,以根据这些新信息调整治疗计划。来自两个商业组织和两个学术组织的研究小组将合作开发这一临床可翻译的策略,最初解决复发的多药耐药表型。NMI-500使用叶酸来特异性地靶向多西紫杉醇(DTX),并使用Gd(一种磁共振成像剂)来定位疾病以及远端转移。已知,以部分叶酸为靶点的NMI-500‘S可促进表达叶酸受体α(FR-a)的肿瘤的摄取。在正常组织中大部分缺失的FR-a已被证明在80%的复发性卵巢肿瘤中过度表达。在乳腺癌中,高FR-α的表达与不良的临床结果有关。NMI-500的成像成分将通过核磁共振造影剂Gd实现,已被证明在与纳米乳剂1结合时可以提高对比度效率。1具体目标将评估和验证组合成像/化疗产品NMI-500的成像、靶向、疗效和药代动力学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mansoor M Amiji其他文献
Mansoor M Amiji的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mansoor M Amiji', 18)}}的其他基金
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
TGX-1214 - 治疗晚期胰腺癌的联合策略
- 批准号:
10607971 - 财政年份:2023
- 资助金额:
$ 66.56万 - 项目类别:
Intranasal gene delivery for Alzheimer’s disease
鼻内基因递送治疗阿尔茨海默病
- 批准号:
10308277 - 财政年份:2021
- 资助金额:
$ 66.56万 - 项目类别:
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
用 MicroRNA 纳米载体重编程 PDAC 中的肿瘤相关巨噬细胞
- 批准号:
9517784 - 财政年份:2017
- 资助金额:
$ 66.56万 - 项目类别:
Integrated Nano-Therapeutics to Overcome Tumor Plasticity and Resistance
综合纳米疗法克服肿瘤可塑性和耐药性
- 批准号:
9165227 - 财政年份:2017
- 资助金额:
$ 66.56万 - 项目类别:
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
用 MicroRNA 纳米载体重编程 PDAC 中的肿瘤相关巨噬细胞
- 批准号:
9382014 - 财政年份:2017
- 资助金额:
$ 66.56万 - 项目类别:
Oral Gene Delivery to Improve Iron Overload Disorders
口服基因递送改善铁过载疾病
- 批准号:
9173116 - 财政年份:2016
- 资助金额:
$ 66.56万 - 项目类别:
Targeted Platinates/siRNA Combination Therapy for Resistant Lung Cancer
靶向铂酸盐/siRNA 联合治疗耐药肺癌
- 批准号:
8688558 - 财政年份:2014
- 资助金额:
$ 66.56万 - 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:
8090583 - 财政年份:2011
- 资助金额:
$ 66.56万 - 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:
8248798 - 财政年份:2011
- 资助金额:
$ 66.56万 - 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:
8450787 - 财政年份:2011
- 资助金额:
$ 66.56万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 66.56万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 66.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 66.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 66.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 66.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 66.56万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 66.56万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 66.56万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 66.56万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 66.56万 - 项目类别:
Studentship